Medical Device Reporting Issues Prompt Edwards Warning Letter
This article was originally published in The Gray Sheet
Edwards Lifesciences failed to report within required time frames six serious adverse events linked to its annuloplasty rings and a replacement heart valve, according to a March 1 1warning letter
You may also be interested in...
Edwards Lifesciences removed a mitral valve repair device from the market in October and submitted a 510(k) for the product in the midst of an FDA inquiry into whether the device was being marketed without proper clearance
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.